An interventional study of Restrata TM Wound Matrix in Diabetic Foot Ulcer, sponsored by Acera Surgical, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Diabetic Foot by Solventum — none open to participants now, none under way, none of them phase 3. Diabetic Foot · Solventum.
Among the 12 studies in Diabetic Foot by Solventum, this one is the only one that started in 2017, is one of 8 with no phase, and was the 10th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.
Browse Diabetic Foot studies →None of the 12 studies in Diabetic Foot by Solventum is open now. The open studies under Diabetic Foot, anywhere →
Of the 137 Diabetic Foot studies recruiting now, 96 (70%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2017.
This study's enrollment of 30 is below the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 48 across the 9 interventional studies, 135 across the 3 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acera Surgical, Inc., one of the names counted as Solventum. Under that name alone:
Acera Surgical, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Diabetic Foot by Solventum, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™). Results of this study may be used to make decisions on whether to conduct additional studies on this particular wound matrix product. RestrataTM has been cleared by the Food and Drug Administration for use in certain types of ulcer treatments, including the type that will be part of this study (diabetic foot ulcers).
Control Group: None (Utilize historical / published data on outcomes using standard of care)
Test Group: Treatment of DFUs with RestrataTM Wound Matrix
Study Type: Interventional
Study Design: Allocation: Non-randomized Endpoint Classification: Efficacy Intervention Model: Direct assignment Masking: Single Blind (Subject) Primary Purpose: Treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has adequate control of diabetes, as demonstrated by one of the following within 30 days of screening:
Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days of the first screening visit:
Dorsum transcutaneous oxygen test (TcPO2) with results
≥30mmHg, OR
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospective, single armed, non-randomized study with direct assignment
Device: Restrata TM Wound Matrix
The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
Percentage of Participants With Wound Closed
from baseline at week 0 to 14 weeks
Time frame: Up to 14 weeks
Change in Wound Area From Baseline
Wound area measurements will be made via tracing acetate every week for 14 weeks.
Time frame: Baseline and weekly for up to 14 weeks
Time to Wound Closure
The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.
Time frame: Baseline up to 14 weeks
| Milestone | Restrata Wound Matrix |
|---|---|
| Started | 30 |
| Completed | 24 |
| Not completed | 6 |
from baseline at week 0 to 14 weeks
| percentage of participants | Restrata Wound Matrix |
|---|---|
| Percentage of Participants With Wound Closed | 75 |
Wound area measurements will be made via tracing acetate every week for 14 weeks.
| % wound area change | Restrata Wound Matrix |
|---|---|
| Change in Wound Area From Baseline | 96 ± 10 |
The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.
| weeks | Restrata Wound Matrix |
|---|---|
| Time to Wound Closure | 6.4 ± 2.5 |
Collected over 3.5 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Restrata Wound Matrix | 0/24 (0%) | 0/24 (0%) | 12/24 (50%) |
| Event | Restrata Wound Matrix |
|---|---|
| InfectionGeneral disorders | 3/24 |
| TraumaGeneral disorders | 2/24 |
| OsteomyelitisGeneral disorders | 2/24 |
| BlisterGeneral disorders | 2/24 |
| FeverGeneral disorders | 1/24 |
| Peripheral vascular diseaseGeneral disorders | 1/24 |
| New ulcerGeneral disorders | 1/24 |
| Age, Categorical(Participants) | Restrata Wound Matrix |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 19 |
| >=65 years | 1 |
| Sex: Female, Male(Participants) | Restrata Wound Matrix |
|---|---|
| Female | 2 |
| Male | 18 |
| Race and Ethnicity Not Collected(Participants) | Restrata Wound Matrix |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Jul 2018, 10 months.
Results were first posted in Apr 2021, 2 years 9 months after primary completion.
Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 10 months is below that.
Counting every sponsor, half of 344 studies reached it within 22 months; a quarter within 9 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.